TxCell Takes Lead Product into Japan

TxCell SA, a French biotechnology company developing immunotherapies using regulatory T-cells to treat severe chronic inflammatory and autoimmune diseases, has been granted a key patent in Japan to cover its lead product Ovasave(R) and its application to inflammatory bowel disease (IBD). 

Issued by The Japan Patent Office, it specifically covers the administration of a composition that consists of at least one human Type?1 Treg cell population directed against a food antigen from the common human diet. The equivalent patent has already been granted in the USA (2015), Australia (2015) and Russia (2013) with other corresponding applications pending.  

“Recent positive developments in both the regulatory field and product approvals means that Japan has become a key market for immunocellular therapy,” said Stéphane Boissel, Chief Executive Officer of TxCell. “The grant of this latest key patent in Japan will help to achieve TxCell’s ambitious objectives in expanding our global reach. In addition, TxCell has dedicated years of effort in research and development to establish a robust international intellectual property portfolio. This patent coverage will be critical for our ongoing efforts to make cellular immunotherapies available to the large number of patients with a variety of conditions with unmet medical need.”